Full Press Release Details
Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
Md., May 17, 2023 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical
company focused on improving outcomes for cancer patients treated with radiation therapy (RT) (the "Company," "Shuttle
Pharmaceuticals"), announced today that its Chief Executive Officer, Anatoly Dritschilo, M.D., will be participating in a Webcast
and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference (the "Conference") on Thursday, May 18, 2023.
Management will also be conducting one-on-one meetings with investors.
Company's webcast presentation will be available for viewing at 9:00 am ET on Thursday, May 18, 2023, on the Company's website
at https://shuttlepharma.com/investor-relations/ or https://wsw.com/webcast/lytham8/shph/2045925. The webcast will also
be archived and available for replay.
Dr. Dritschilo will be participating in a panel titled, "Advancements in the Fight Against Cancer." This panel, also
to be conducted virtually, will be held on Thursday, May 18, 2023, at 11:00 am ET. To access the panel, please visit: https://wsw.com/webcast/lytham8/panel2/2271150.
Dritschilo will be participating in virtual one-on-one meetings throughout the Conference. To arrange a meeting with Dr. Dritschilo,
please contact Lytham Partners at 1x1@lythampartners.com or register at https://www.lythampartners.com/spring2023invreg/.
Shuttle Pharmaceuticals
in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty
pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve
the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects
of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim
to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Anatoly Dritschilo, M.D., Chief Executive Officer